| Basics |
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
|
| IPO Date: |
November 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.99B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.00 | 2.80%
|
| Avg Daily Range (30 D): |
$0.55 | 2.45%
|
| Avg Daily Range (90 D): |
$0.59 | 2.47%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.12M |
| Avg Daily Volume (30 D): |
2.4M |
| Avg Daily Volume (90 D): |
2.11M |
| Trade Size |
| Avg Trade Size (Sh.): |
77 |
| Avg Trade Size (Sh.) (30 D): |
74 |
| Avg Trade Size (Sh.) (90 D): |
73 |
| Institutional Trades |
| Total Inst.Trades: |
7,776 |
| Avg Inst. Trade: |
$3.4M |
| Avg Inst. Trade (30 D): |
$3.92M |
| Avg Inst. Trade (90 D): |
$4.47M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.36M |
| Avg Closing Trade (30 D): |
$8.51M |
| Avg Closing Trade (90 D): |
$9.19M |
| Avg Closing Volume: |
192.87K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.36
|
$1.71
|
$-.33
|
|
Diluted EPS
|
$.36
|
$1.67
|
$-.33
|
|
Revenue
|
$ 1.02B
|
$ 458.58M
|
$ 178.49M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 44.99M
|
$ 215.72M
|
$ -42.15M
|
|
Operating Income / Loss
|
$ 80.41M
|
$ 223.18M
|
$ -33.29M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 82.36M
|
$ 109.14M
|
$ 11.64M
|
|
PE Ratio
|
66.43
|
|
|
| Splits |
|
Mar 19, 2004:
1:200
|
|
|
|
